Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q3 EPS of $1.51, versus $1.15 reported last year. Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings Guidance Management Comments

Aegis Maintains Buy on Valeant (VRX); One-Time Items Don't Reflect True OperationsOctober 31, 2013 2:14 PM Goldman Sachs Comments on Valeant Pharmaceuticals' (VRX) Q3 ResultsOctober 31, 2013 11:29 AM